Value through Innovation

main navigation

jump to content to meta navigation
Headillu

page content

jump to main navigation to meta navigation

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
18.07.2007 EUROPEAN Porcine Circovirus (PCV-2) Annual Research Award launched by Boehringer Ingelheim
11.07.2007 Further phase III data shows dabigatran etexilate, a new oral anticoagulant, is effective and safe in preventing venous thromboembolism after orthopaedic surgery - For medical media, outside the US only
02.07.2007 A million doses of hope against Aids - For medical media, outside the US only
18.06.2007 New study shows that telmisartan has greater renoprotective potential than losartan in hypertensive patients with type 2 diabetes - For medical media, outside the US only
18.06.2007 More than half of hypertensive patients remain uncontrolled and thus at higher risk of heart attack and stroke - telmisartan may decrease this risk. - For medical media, outside the US only
14.06.2007 Boehringer Ingelheim initiates SPRING study of Aptivus® (tipranavir) in diverse group of highly treatment-experienced HIV-positive patients - For medical media, outside the US only
08.06.2007 Efficacy of Boehringer Ingelheim’s pramipexole (Mirapexin®/Sifrol®) also demonstrated in patients with daytime RLS symptoms - For medical media, outside the US only
31.05.2007 New research confirms the benefit of extended-release dipyridamole plus ASA for preventing recurrent stroke in low- and high-risk patients - For medical media, outside the US only
23.05.2007 Workplace burden of depression magnified by co-morbid fatigue and anxiety, new study shows
23.05.2007 In new study, Duloxetine was equally effective, regardless of switch method, in reducing painful symptoms in SSRI non- or partial-responders with depression
15.05.2007 Boehringer Ingelheim further intensifies fight against AIDS
10.05.2007 Boehringer Ingelheim initiates international head-to-head HIV/AIDS trial - For medical media, outside the US only
01.04.2007 Investigation of the European Commission
27.03.2007 Boehringer Ingelheim grows faster than the market once again - Spiriva®, Micardis® and Flomax®/Alna® the top products
19.03.2007 In new study, Duloxetine reduced non-specific pain and emotional symptoms associated with depression
26.02.2007 U.S. regulators approve Cymbalta® for treatment of generalised anxiety disorder - For medical media, outside the US only
16.02.2007 Closing of Boehringer Ingelheim`s divestiture of Pharmaton SA to Ideasphere cancelled
08.02.2007 Multidisciplinary Expert Panel highlights Boehringer Ingelheim’s continuing commitment to research in Parkinson’s disease - For medical media, outside the US only
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
back to top

Contact

Boehringer Ingelheim GmbH

Corporate Headquarters
Binger Str. 173
55216 Ingelheim
Germany


Phone +49 / 6132 / 77 0
Fax +49 / 6132 / 72 0

media contacts

RSS feeds allow you to receive latest news and information about Boehringer Ingelheim.

subscribe to RSS Feed